ArticleScientific reports2025
Determination of the median effective dose of sufentanil combined with remimazolam in inhibiting tracheal intubation response.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- ECDrug design, development and therapy · 2026Trial
- Topical Airway Lidocaine Spray Reduces the 95% Effective Dose of Sufentanil for Blunting Hemodynamic Response to Tracheal Intubation in Elderly Patients: A Biased-Coin Up-and-Down Sequential Allocation Trial.Drug design, development and therapy · 2026Trial
- Article
- Establishing the Median Effective Dose of Tegileridine for Immediate Postoperative Analgesia Following Laparoscopic Colorectal Cancer Surgery: A Sequential Dose-Finding Study.Drug design, development and therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
To determine the median effective dose (ED50) and 95% effective dose (ED95) of sufentanil combined with remimazolam for inhibiting the tracheal intubation response in patients undergoing general anesthesia and to evaluate the hemodynamic stability and adverse events associated with this drug combination. This prospective dose-finding study used Dixon's up-and-down sequential allocation method. A total of 36 patients undergoing general anesthesia surgery between April 2024 and June 2024 were enrolled. Patients were administered remimazolam for induction, followed by sufentanil at an initial dose of 0.4 µg/kg, with subsequent doses adjusted based on the presence or absence of an intubation response. The primary outcome was the ED50 of sufentanil combined with remimazolam, and the secondary outcomes included patient baseline characteristics, hemodynamic parameters, and adverse events. The ED50 and ED95 of sufentanil for inhibiting tracheal intubation response were 0.374 µg/kg (95% CI: 0.342-0.402 µg/kg) and 0.436 µg/kg (95% CI: 0.406-0.586 µg/kg), respectively. Patients with a positive tracheal intubation response had significantly higher heart rates and mean arterial pressures and a higher incidence of hypertension. The ED50 and ED95 of sufentanil combined with remimazolam for inhibiting the tracheal intubation response in patients undergoing general anesthesia were 0.374 and 0.436 µg/kg, respectively. This study provides valuable insights into the dosing of these drugs for effective anesthesia induction and hemodynamic control during tracheal intubation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.